Bayer Profoundly Impacted by Glyphosate Litigation


Following the third adverse verdict in civil trials alleging that glyphosate, the active ingredient of Roundup® is responsible for non-Hodgkin lymphoma, Bayer is experiencing shareholder disaffection. Since the purchase of Monsanto by Bayer, market capitalization has declined by 40 percent to $60 billion, less than the $63 billion expended to purchase Monsanto.

Based on scientific evidence that glyphosate is not carcinogenic, Bayer is determined to defend all actions notwithstanding the 13,000 plaintiffs who have filed claims.

The management of Bayer are opposing any suggestions to break up the company although specific assets peripheral to the core of the business have been sold or are offered for sale.